ClinicalTrials.gg
CompletedNCT00266630Updated Dec 28, 2010Results posted

Efficacy and Safety of Olanzapine in the Extended Treatment for Manic or Mixed Episode of Bipolar I Disorder

A Phase 3 interventional study of olanzapine and lithium in Manic or Mixed Episode Associated With Bipolar I Disorder, sponsored by Eli Lilly and Company. Completed at 11 sites in Japan. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2010-12-28.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
139
Allocation
Non-randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

The efficacy and safety of the extended treatment to patients with most recent episode manic or mixed who completed previous double blind study (F1D-JE-BMAC [Study BMAC]) will be examined.

02

Conditions studied

  • Manic or Mixed Episode Associated With Bipolar I Disorder

Browse trials for

03

In context

Mania

167 studies on the registry are indexed under Mania; 14 are open to participants now.

This study's enrollment of 139 is above the median of 89 across 139 interventional studies indexed under Mania.

Browse Mania studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Enrolled in and completed Study BMAC (NCT00129220), or those who discontinued Study BMAC at Visit 4 or Visit 5 due to lack of efficacy and for whom the Young Mania Rating Scale (YMRS) total score at the time of discontinuation was not lower than that at baseline of Study BMAC
  • Are diagnosed as "294.4x Bipolar I Disorder, Most Recent Episode Manic" or "296.6x Bipolar I Disorder, Most Recent Episode Mixed," as determined by the Mini-International Neuropsychiatric Interview (MINI)

Exclusion criteria

Exclusion Criteria:

  • Have a diagnosis of diabetes mellitus
  • Significant protocol deviation in Study BMAC
  • The actual date of the final visit of Study BMAC is 4 days or more later than the scheduled date of first visit in Study BMEX
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Olanzapine Monotherapy

    Olanzapine extension for Study BMAC patients who completed Visit 8. Patients received olanzapine 5-20 mg for 18 weeks.

    Drug: olanzapine

  • Experimental
    Olanzapine + Mood Stabilizer

    Olanzapine extension for Study BMAC patients who discontinued at Visit 4 or 5. Patients received an initial dose of olanzapine 10 mg for 1 week and subsequent doses of olanzapine 5-20 mg for 17 weeks. Patients received one (1) mood stabilizer (lithium, valproate or carbamazepine) for 18 weeks.

    Drug: olanzapine · Drug: lithium · Drug: valproate · Drug: carbamazepine

Interventions

  • oral, daily

    Also known as: LY170053, Zyprexa

  • Dose adjusted according to local package insert

  • Dose adjusted according to local package insert

  • Dose adjusted according to local package insert

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Scores - Olanzapine Monotherapy Arm Only

    The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.

    Time frame: baseline through 18 weeks

  2. Number of Participants With Response of Manic Symptoms - Olanzapine Monotherapy Arm Only

    Defined by a 50% or more reduction in YMRS total score from baseline in Study BMAC to endpoint. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.

    Time frame: baseline through 18 weeks

  3. Number of Participants With Remission of Mania - Olanzapine Monotherapy Arm Only

    Remission of Mania was defined as a YMRS total score of less than or equal to 12 at endpoint. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.

    Time frame: baseline through 18 weeks

  4. Number of Participants With Relapse of Manic Symptoms - Olanzapine Monotherapy Arm Only

    Patients achieved remission in Study BMAC (defined as YMRS total score \<=12 and HAMD-17 total score \<=7) and obtained YMRS total score of \>=15 at any time during Study BMEX. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.

    Time frame: baseline through 18 weeks

Secondary outcomes

  1. Change From Baseline to Endpoint on the YMRS Total Score - Olanzapine + Mood Stabilizer Only

    The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

    Time frame: baseline through 18 weeks

  2. Clinical Global Impressions - Bipolar Version, Severity of Illness (CGI-BP) Overall, Visit Data

    Measures severity of the patient's overall severity of bipolar symptoms (1=normal, not at all ill; 7=among the most extremely ill patients).

    Time frame: baseline, Weeks 1, 2, 4, 6, 10, 14, 18

  3. Number of Participants Who Experienced Switch to Symptomatic Depression as Measured by the Hamilton Depression Scale - 17 Item Version (HAMD-17)

    Incidence of depressive symptoms was defined as a score of equal to or more than 13 points on the HAMD-17. The 17-item HAMD measures depression severity. Each item was evaluated and scored a 3-point scale (e.g. absent, mild, marked) or a 5-point scale (e.g. absent, mild, moderate, severe, very severe). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).

    Time frame: baseline through 18 weeks

  4. Number of Participants With Relapse of Depressive Symptoms

    Assessed were participants meeting remission criteria for bipolar disorder in Study BMAC and have a HAMD-17 total score greater than or equal to 13 at any time. The 17-item HAMD measures depression severity. Each item was evaluated and scored using a 3-point scale (e.g. absent, mild, marked) or a 5-point scale (e.g. absent, mild, moderate, severe, very severe). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).

    Time frame: baseline through 18 weeks

  5. Number of Participants Who Experienced Remission of Bipolar Disorder

    Participants who had equal to or less than 12 points in YMRS total score and equal to or less than 7 points in HAMD-17 total score at 18 weeks. YMRS: 11-item scale, measures the severity of manic episodes. 4 items are rated from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total: 0 to 60. The 17-item HAMD measures depression severity. Each item was evaluated and scored using a 3-point scale or a 5-point scale. HAMD-17 total score: 0 (normal) to 52 (severe).

    Time frame: Week 18

  6. Positive and Negative Syndrome Scale Positive Scores - Visit Data

    Assesses positive symptoms associated with schizophrenia. 7 items make up the Positive scale. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total Positive Subscale scores range from 7 to 49. For the analysis, the score was converted to 0 to 6 for each item range; hence, the total score ranges from 0 to 42.

    Time frame: baseline, Weeks 1, 2, 4, 6, 10, 14, 18

  7. Number of Participants Who Switched to Syndromic Depression

    As defined as a shift from a Manic Episode at baseline to a Major Depressive Episode, at any post baseline visit, based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision.

    Time frame: baseline through 18 weeks

  8. Maximum Change From Baseline to Endpoint on the Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS) - Total Score

    A scale used to assess the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Parkinsonism is assessed by the total points of items 1 to 5; akathisia, dystonia and dyskinesia are assessed by the points given to the corresponding items.

    Time frame: baseline through 18 weeks

  9. Number of Participants With Treatment-Emergent Parkinsonism Based on DIEPSS Scores

    DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). Parkinsonism is assessed by the total points of items 1 to 5 (total score of 0 to 20). Treatment-emergent parkinsonism was defined as a score of equal or greater than 3 on 1 item, equal or greater than 2 on 2 items, or an increase of equal or greater than 3 from baseline on the parkinsonism total.

    Time frame: baseline through 18 weeks

  10. Number of Participants With Treatment-Emergent Akathisia Based on DIEPSS Scores

    DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Treatment-emergent akathisia was defined as a score of equal or more than 2 or an increase of equal or more than 2 points from baseline on the akathisia item (total score possible 0 to 4 points).

    Time frame: baseline through 18 weeks

  11. Number of Participants With Treatment-Emergent Dystonia Based on DIEPSS Scores

    DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Treatment-emergent dystonia was defined as a score equal or more than 2 or an increase of equal or more than 2 points from baseline on the dystonia item (total score possible 0 to 4 points).

    Time frame: baseline through 18 weeks

  12. Number of Participants With Treatment-Emergent Dyskenisia Based on DIEPSS Scores

    DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Treatment-emergent dyskenisia was defined as a score of equal or more than 2 or an increase of equal to or more than 2 points from baseline on the dyskenisia item (total score possible 0 to 4 points).

    Time frame: baseline through 18 weeks

  13. Number of Participants With Potentially Clinically Significant Changes in Laboratory Analytes

    Triglycerides: high limit equal to or more than 500 milligram/deciliter (mg/dL); Glucose (non-fasting): low limit 2.4975 mmol/liter (L); high limit 13.875 mmol/L; Glucose (fasting): low limit 2.4975 mmol/L; high limit 6.993 mmol/L.

    Time frame: baseline through 18 weeks

  14. Number of Participants With Potentially Clinically Significant Changes in Vital Signs and Weight

    Low systolic blood pressure (SBP): \<=90 millimeter mercury (mmHg) and decrease of \>=20 mmHg; High SBP: \>=180 mmHg and increase of \>=20 mmHg; Low diastolic blood pressure (DBP): \<=50 mmHg and decrease of \>=15 mmHg; High DBP: \>=105 mmHg and increase of \>=15 mmHg; Low pulse: \<50 beats per minute (bpm) and decrease of \>=15 bpm; High pulse: \>120 bpm and an increase of \>=15 bpm; Low weight: decrease of \>=7%; High weight: increase of \>=7%;

    Time frame: baseline through 18 weeks

  15. Number of Participants With Potentially Clinically Significant Changes in Electrocardiograms - High Fridericia Corrected QT Interval (QTcF)

    High QTcF: more than or equal to 450 milliseconds (msec) for males; more than or equal to 470 milliseconds (msec) for females

    Time frame: baseline through 18 weeks

  16. Number of Participants With Treatment-emergent Abnormal, High, or Low Laboratory Values

    High density lipoprotein: males low 40 milligram/deciliter (mg/dL), high 80 mg/dL; females low 40 mg/dL, high 90 mg/dL. Low density lipoprotein (LDL): males and females low 70 mg/dL, high 139 mg/dL. Hemoglobin A1C (HBA1C): males and females low 4.3%, high 5.8%.

    Time frame: baseline through 18 weeks

07

Results

Posted Jun 29, 2010
Limitations and caveats
Identified errors were corrected.

Participant flow

Participant flow — Overall Study
MilestoneOlanzapine MonotherapyOlanzapine + Mood Stabilizer
Started10039
Completed5811
Not completed4228
Withdrew: Adverse event86
Withdrew: Lack of efficacy14
Withdrew: Entry criteria not met10
Withdrew: Protocol violation13
Withdrew: Physician decision12
Withdrew: Withdrawal by subject102
Withdrew: Lost to follow-up10
Withdrew: Other1911

Outcome measures

PrimaryChange From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Scores - Olanzapine Monotherapy Arm Only

The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.

Time frame:
baseline through 18 weeks
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Scores - Olanzapine Monotherapy Arm Only
units on a scaleOlanzapine Monotherapy
Change From Baseline to Endpoint in Young Mania Rating Scale (YMRS) Total Scores - Olanzapine Monotherapy Arm Only-3.0 ± 5.6
Statistical analysis
  • Olanzapine Monotherapy · Mean difference (final values): -3.0 · 95% CI -4.10 to -1.90
PrimaryNumber of Participants With Response of Manic Symptoms - Olanzapine Monotherapy Arm Only

Defined by a 50% or more reduction in YMRS total score from baseline in Study BMAC to endpoint. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.

Time frame:
baseline through 18 weeks
Reported as:
Number · participants
Number of Participants With Response of Manic Symptoms - Olanzapine Monotherapy Arm Only
participantsOlanzapine Monotherapy
Number of Participants With Response of Manic Symptoms - Olanzapine Monotherapy Arm Only97
PrimaryNumber of Participants With Remission of Mania - Olanzapine Monotherapy Arm Only

Remission of Mania was defined as a YMRS total score of less than or equal to 12 at endpoint. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.

Time frame:
baseline through 18 weeks
Reported as:
Number · participants
Number of Participants With Remission of Mania - Olanzapine Monotherapy Arm Only
participantsOlanzapine Monotherapy
Number of Participants With Remission of Mania - Olanzapine Monotherapy Arm Only93
PrimaryNumber of Participants With Relapse of Manic Symptoms - Olanzapine Monotherapy Arm Only

Patients achieved remission in Study BMAC (defined as YMRS total score \<=12 and HAMD-17 total score \<=7) and obtained YMRS total score of \>=15 at any time during Study BMEX. The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60. The primary objective was only interested in the effects in the olanzapine monotherapy arm.

Time frame:
baseline through 18 weeks
Reported as:
Number · participants
Number of Participants With Relapse of Manic Symptoms - Olanzapine Monotherapy Arm Only
participantsOlanzapine Monotherapy
Number of Participants With Relapse of Manic Symptoms - Olanzapine Monotherapy Arm Only3
SecondaryChange From Baseline to Endpoint on the YMRS Total Score - Olanzapine + Mood Stabilizer Only

The YMRS is an 11-item scale that measures the severity of manic episodes. Four items are rated on a scale from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated on a scale from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total score ranges from 0 to 60.

Time frame:
baseline through 18 weeks
Reported as:
Mean · units on a scale
Change From Baseline to Endpoint on the YMRS Total Score - Olanzapine + Mood Stabilizer Only
units on a scaleOlanzapine + Mood Stabilizer
Change From Baseline to Endpoint on the YMRS Total Score - Olanzapine + Mood Stabilizer Only-19.8 ± 17.8
Statistical analysis
  • Olanzapine + Mood Stabilizer · Mean difference (final values): -19.8 · 95% CI -25.58 to -14.06
SecondaryClinical Global Impressions - Bipolar Version, Severity of Illness (CGI-BP) Overall, Visit Data

Measures severity of the patient's overall severity of bipolar symptoms (1=normal, not at all ill; 7=among the most extremely ill patients).

Time frame:
baseline, Weeks 1, 2, 4, 6, 10, 14, 18
Reported as:
Mean · units on a scale
Clinical Global Impressions - Bipolar Version, Severity of Illness (CGI-BP) Overall, Visit Data
units on a scaleOlanzapine MonotherapyOlanzapine + Mood Stabilizer
baseline1.9 ± 1.04.7 ± 0.8
1 week1.8 ± 1.04.1 ± 1.2
2 weeks1.8 ± 1.03.7 ± 1.3
4 weeks1.7 ± 1.03.5 ± 1.6
6 weeks1.7 ± 1.13.4 ± 1.7
10 weeks1.7 ± 1.13.0 ± 1.8
14 weeks1.8 ± 1.23.0 ± 1.9
18 weeks endpoint1.7 ± 1.22.9 ± 2.0
SecondaryNumber of Participants Who Experienced Switch to Symptomatic Depression as Measured by the Hamilton Depression Scale - 17 Item Version (HAMD-17)

Incidence of depressive symptoms was defined as a score of equal to or more than 13 points on the HAMD-17. The 17-item HAMD measures depression severity. Each item was evaluated and scored a 3-point scale (e.g. absent, mild, marked) or a 5-point scale (e.g. absent, mild, moderate, severe, very severe). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).

Time frame:
baseline through 18 weeks
Reported as:
Number · participants
Number of Participants Who Experienced Switch to Symptomatic Depression as Measured by the Hamilton Depression Scale - 17 Item Version (HAMD-17)
participantsOlanzapine MonotherapyOlanzapine + Mood Stabilizer
Number of Participants Who Experienced Switch to Symptomatic Depression as Measured by the Hamilton Depression Scale - 17 Item Version (HAMD-17)41
SecondaryNumber of Participants With Relapse of Depressive Symptoms

Assessed were participants meeting remission criteria for bipolar disorder in Study BMAC and have a HAMD-17 total score greater than or equal to 13 at any time. The 17-item HAMD measures depression severity. Each item was evaluated and scored using a 3-point scale (e.g. absent, mild, marked) or a 5-point scale (e.g. absent, mild, moderate, severe, very severe). The total score of HAMD-17 may range from 0 (normal) to 52 (severe).

Time frame:
baseline through 18 weeks
Reported as:
Number · participants
Number of Participants With Relapse of Depressive Symptoms
participantsOlanzapine Monotherapy
Number of Participants With Relapse of Depressive Symptoms4
SecondaryNumber of Participants Who Experienced Remission of Bipolar Disorder

Participants who had equal to or less than 12 points in YMRS total score and equal to or less than 7 points in HAMD-17 total score at 18 weeks. YMRS: 11-item scale, measures the severity of manic episodes. 4 items are rated from 0 (symptom not present) to 8 (symptom extremely severe). The remaining items are rated from 0 (symptom not present) to 4 (symptom extremely severe). The YMRS total: 0 to 60. The 17-item HAMD measures depression severity. Each item was evaluated and scored using a 3-point scale or a 5-point scale. HAMD-17 total score: 0 (normal) to 52 (severe).

Time frame:
Week 18
Reported as:
Number · participants
Number of Participants Who Experienced Remission of Bipolar Disorder
participantsOlanzapine MonotherapyOlanzapine + Mood Stabilizer
Number of Participants Who Experienced Remission of Bipolar Disorder5412
SecondaryPositive and Negative Syndrome Scale Positive Scores - Visit Data

Assesses positive symptoms associated with schizophrenia. 7 items make up the Positive scale. Each item is rated on a scale from 1 (symptom not present) to 7 (symptoms extremely severe). Total Positive Subscale scores range from 7 to 49. For the analysis, the score was converted to 0 to 6 for each item range; hence, the total score ranges from 0 to 42.

Time frame:
baseline, Weeks 1, 2, 4, 6, 10, 14, 18
Reported as:
Mean · units on a scale
Positive and Negative Syndrome Scale Positive Scores - Visit Data
units on a scaleOlanzapine MonotherapyOlanzapine + Mood Stabilizer
baseline7.7 ± 1.812.5 ± 5.7
1 week7.5 ± 1.610.5 ± 4.1
2 weeks7.5 ± 1.410.1 ± 3.9
4 weeks7.4 ± 1.410.1 ± 5.4
6 weeks7.3 ± 1.210.1 ± 5.4
10 weeks7.4 ± 1.79.9 ± 5.4
14 weeks7.4 ± 1.79.9 ± 5.4
18 week endpoint7.4 ± 1.79.9 ± 5.4
SecondaryNumber of Participants Who Switched to Syndromic Depression

As defined as a shift from a Manic Episode at baseline to a Major Depressive Episode, at any post baseline visit, based on Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Text Revision.

Time frame:
baseline through 18 weeks
Reported as:
Number · participants
Number of Participants Who Switched to Syndromic Depression
participantsOlanzapine MonotherapyOlanzapine + Mood Stabilizer
Number of Participants Who Switched to Syndromic Depression84
SecondaryMaximum Change From Baseline to Endpoint on the Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS) - Total Score

A scale used to assess the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items for the assessment of individual symptoms are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Parkinsonism is assessed by the total points of items 1 to 5; akathisia, dystonia and dyskinesia are assessed by the points given to the corresponding items.

Time frame:
baseline through 18 weeks
Reported as:
Mean · units on a scale
Maximum Change From Baseline to Endpoint on the Drug Induced Extra-Pyramidal Symptoms Scale (DIEPSS) - Total Score
units on a scaleOlanzapine MonotherapyOlanzapine + Mood Stabilizer
Baseline0.35 ± 1.010.18 ± 0.60
Maximum Change from baseline to endpoint0.05 ± 1.210.64 ± 1.51
SecondaryNumber of Participants With Treatment-Emergent Parkinsonism Based on DIEPSS Scores

DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). Parkinsonism is assessed by the total points of items 1 to 5 (total score of 0 to 20). Treatment-emergent parkinsonism was defined as a score of equal or greater than 3 on 1 item, equal or greater than 2 on 2 items, or an increase of equal or greater than 3 from baseline on the parkinsonism total.

Time frame:
baseline through 18 weeks
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Parkinsonism Based on DIEPSS Scores
participantsOlanzapine MonotherapyOlanzapine + Mood Stabilizer
Number of Participants With Treatment-Emergent Parkinsonism Based on DIEPSS Scores13
SecondaryNumber of Participants With Treatment-Emergent Akathisia Based on DIEPSS Scores

DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Treatment-emergent akathisia was defined as a score of equal or more than 2 or an increase of equal or more than 2 points from baseline on the akathisia item (total score possible 0 to 4 points).

Time frame:
baseline through 18 weeks
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Akathisia Based on DIEPSS Scores
participantsOlanzapine MonotherapyOlanzapine + Mood Stabilizer
Number of Participants With Treatment-Emergent Akathisia Based on DIEPSS Scores32
SecondaryNumber of Participants With Treatment-Emergent Dystonia Based on DIEPSS Scores

DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Treatment-emergent dystonia was defined as a score equal or more than 2 or an increase of equal or more than 2 points from baseline on the dystonia item (total score possible 0 to 4 points).

Time frame:
baseline through 18 weeks
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Dystonia Based on DIEPSS Scores
participantsOlanzapine MonotherapyOlanzapine + Mood Stabilizer
Number of Participants With Treatment-Emergent Dystonia Based on DIEPSS Scores01
SecondaryNumber of Participants With Treatment-Emergent Dyskenisia Based on DIEPSS Scores

DIEPSS assesses the extrapyramidal symptoms attributable to antipsychotics. Consists of 9 items (8 to assess individual symptoms and 1 to assess global severity). Each item is assessed from 0 (none, normal) to 4 (severe). The total points of 8 items are defined as DIEPSS total (0 to 32 points). The items are classified into 4 categories of parkinsonism, akathisia, dystonia and dyskinesia. Treatment-emergent dyskenisia was defined as a score of equal or more than 2 or an increase of equal to or more than 2 points from baseline on the dyskenisia item (total score possible 0 to 4 points).

Time frame:
baseline through 18 weeks
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Dyskenisia Based on DIEPSS Scores
participantsOlanzapine MonotherapyOlanzapine + Mood Stabilizer
Number of Participants With Treatment-Emergent Dyskenisia Based on DIEPSS Scores00
SecondaryNumber of Participants With Potentially Clinically Significant Changes in Laboratory Analytes

Triglycerides: high limit equal to or more than 500 milligram/deciliter (mg/dL); Glucose (non-fasting): low limit 2.4975 mmol/liter (L); high limit 13.875 mmol/L; Glucose (fasting): low limit 2.4975 mmol/L; high limit 6.993 mmol/L.

Time frame:
baseline through 18 weeks
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Changes in Laboratory Analytes
participantsOlanzapine MonotherapyOlanzapine + Mood Stabilizer
High triglycerides; n=100, n=3852
Low glucose (non-fasting); n=64, n=2800
High glucose (non-fasting); n=64, n=2800
Low glucose (fasting); n=40, n=600
High glucose (fasting); n=40, n=630
SecondaryNumber of Participants With Potentially Clinically Significant Changes in Vital Signs and Weight

Low systolic blood pressure (SBP): \<=90 millimeter mercury (mmHg) and decrease of \>=20 mmHg; High SBP: \>=180 mmHg and increase of \>=20 mmHg; Low diastolic blood pressure (DBP): \<=50 mmHg and decrease of \>=15 mmHg; High DBP: \>=105 mmHg and increase of \>=15 mmHg; Low pulse: \<50 beats per minute (bpm) and decrease of \>=15 bpm; High pulse: \>120 bpm and an increase of \>=15 bpm; Low weight: decrease of \>=7%; High weight: increase of \>=7%;

Time frame:
baseline through 18 weeks
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Changes in Vital Signs and Weight
participantsOlanzapine MonotherapyOlanzapine + Mood Stabilizer
Low systolic blood pressure62
High systolic blood pressure00
Low diastolic blood pressure41
High diastolic blood pressure10
Low weight31
High weight1710
Low pulse00
High pulse00
SecondaryNumber of Participants With Potentially Clinically Significant Changes in Electrocardiograms - High Fridericia Corrected QT Interval (QTcF)

High QTcF: more than or equal to 450 milliseconds (msec) for males; more than or equal to 470 milliseconds (msec) for females

Time frame:
baseline through 18 weeks
Reported as:
Number · participants
Number of Participants With Potentially Clinically Significant Changes in Electrocardiograms - High Fridericia Corrected QT Interval (QTcF)
participantsOlanzapine MonotherapyOlanzapine + Mood Stabilizer
Number of Participants With Potentially Clinically Significant Changes in Electrocardiograms - High Fridericia Corrected QT Interval (QTcF)00
SecondaryNumber of Participants With Treatment-emergent Abnormal, High, or Low Laboratory Values

High density lipoprotein: males low 40 milligram/deciliter (mg/dL), high 80 mg/dL; females low 40 mg/dL, high 90 mg/dL. Low density lipoprotein (LDL): males and females low 70 mg/dL, high 139 mg/dL. Hemoglobin A1C (HBA1C): males and females low 4.3%, high 5.8%.

Time frame:
baseline through 18 weeks
Reported as:
Number · participants
Number of Participants With Treatment-emergent Abnormal, High, or Low Laboratory Values
participantsOlanzapine MonotherapyOlanzapine + Mood Stabilizer
Low high density lipoprotein (HDL); n=93, n=36103
High high density lipoprotein (HDL); n=95, n=3751
Low low density lipoprotein (LDL); n=97; n=3711
High low density lipoprotein (LDL); n=71, n=312411
Low hemoglobin A1C (HBA1C); n=100, n=3911
High hemoglobin A1C (HBA1C); n=97, n=3820

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Olanzapine Monotherapy—1/100 (1%)59/100 (59%)
Olanzapine + Mood Stabilizer—0/39 (0%)31/39 (79.5%)
Most frequent serious events
Most frequent serious events
EventOlanzapine MonotherapyOlanzapine + Mood Stabilizer
Radius fractureInjury, poisoning and procedural complications1/1000/39
Most frequent other events
Showing 10 of 14
Most frequent other events
EventOlanzapine MonotherapyOlanzapine + Mood Stabilizer
SomnolenceNervous system disorders15/1007/39
NasopharyngitisInfections and infestations17/1006/39
Blood triglycerides increasedInvestigations5/1006/39
Weight increasedInvestigations9/1005/39
ConstipationGastrointestinal disorders3/1003/39
Alanine aminotransferase increasedInvestigations2/1003/39
Blood cholesterol increasedInvestigations3/1003/39
Depressive symptomPsychiatric disorders7/1002/39
ThirstGeneral disorders5/1002/39
ContusionInjury, poisoning and procedural complications2/1002/39

Baseline characteristics

Age Continuous
Age Continuous(years)Olanzapine MonotherapyOlanzapine + Mood StabilizerTotal
Mean41.8 ± 11.743.2 ± 11.142.2 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)Olanzapine MonotherapyOlanzapine + Mood StabilizerTotal
Female592180
Male411859
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Olanzapine MonotherapyOlanzapine + Mood StabilizerTotal
Japanese10039139
Region of Enrollment
Region of Enrollment(participants)Olanzapine MonotherapyOlanzapine + Mood StabilizerTotal
Japan10039139
Current Episode - Mixed or Manic
Current Episode - Mixed or Manic(participants)Olanzapine MonotherapyOlanzapine + Mood StabilizerTotal
Manic8839127
Mixed12012
Current Episode - Psychotic or Nonpsychotic
Current Episode - Psychotic or Nonpsychotic(participants)Olanzapine MonotherapyOlanzapine + Mood StabilizerTotal
Psychotic13922
Nonpsychotic8730117
Rapid Cyclers
Rapid Cyclers(participants)Olanzapine MonotherapyOlanzapine + Mood StabilizerTotal
Rapid Cyclers7310
Non-Rapid Cyclers9336129
Clinical Global Impressions - Bipolar Version, Severity of Illness (CGI-BP) overall
Clinical Global Impressions - Bipolar Version, Severity of Illness (CGI-BP) overall(units on a scale)Olanzapine MonotherapyOlanzapine + Mood StabilizerTotal
Mean1.9 ± 1.04.7 ± 0.82.7 ± 1.6

4 further baseline measures are reported on the registry.

08

Study locations

11 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Akita, 010-1654, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Chiba, 292-0061, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fukuoka, 812-8582, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gunma, 371-8511, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hokkaido, 005-0004, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hyogo, 663-8501, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Nara, 634-8522, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Okayama, 710-0055, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Okinawa, 900-0005, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Saitama, 343-0032, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tokyo, 151-0053, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2005, a primary completion of May 2009 and a completion of May 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2005
First posted
Dec 19, 2005
Start
Nov 2005
Primary completionActual
May 2009
CompletionActual
May 2009
Results first posted
Jun 29, 2010
Last update
Dec 28, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00266630
First posted
Dec 19, 2005
Start date
Nov 2005
Primary completion
May 2009
Completion
May 2009
Results posted
Jun 29, 2010
Last update
Dec 28, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT-5 hours, EST)
study director · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olanzapine

Start the discussion